ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2025
Prevalence and epidemiology of enterovirus species in a pediatric oncology patient population.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEnteroviruses (EV) are associated with a range of syndromes including respiratory infections. Non-polio enteroviruses like EV-D68 can cause more severe symptoms in children, and immunocompromised individuals. The goal of this study was to determine the prevalence and genotypes of EV in a pediatric oncology patient population.
methodsPediatric patients (<18 years old) testing positive for Rhinovirus/Enterovirus (RV/EV) by multiplexed respiratory pathogens panels between September and December 2022 and 2023 were included in the study. RV/EV positive nasopharyngeal swabs (NPS) specimens were further characterized using pan-enterovirus RT-PCR, EV-D68 RT-PCR and Whole genome sequencing (WGS). Clinical characteristics of EV positive patients and matched controls were extracted from the clinical information system.
resultsAcross the two study periods, 3.8 % (9/238) and 3.6 % (8/225) EV were identified in RV/EV positives NPS in 2022 and 2023 respectively. The most prevalent EV species were EV-D68 (3/9, 33 %) and Coxsackievirus A6 (3/9, 33 %). All three patients with EV-D68 were male with an underlying diagnosis of acute lymphoblastic lymphoma or neuroblastoma. Besides, the EV-D68 detections were only from the 2022 NPS samples. There were no differences in symptoms severity between patients with or without EV infections.
conclusionsThe prevalence of EV during the study periods was low in this patient population and not associated with severe symptoms. However, further exploration is required to understand the relationship between EV infection and patient symptoms since this study was limited by the low EV detection. Larger studies are needed to further characterize EV infections in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.